Valuation: Bicycle Therapeutics plc

Market Cap 269M 234M 218M 200M 378M 25.72B 384M 2.57B 1.01B 12.81B 1.01B 990M 42.94B P/E 2026 *
-1.44x
P/E 2027 * -1.68x
Enterprise Value -182M -158M -147M -135M -255M -17.35B -259M -1.73B -680M -8.64B -683M -668M -28.96B EV / Sales 2026 *
-10.6x
EV / Sales 2027 * -20.2x
Free-Float
71.44%
Yield 2026 *
-
Yield 2027 * -
1 day-3.74%
1 week-0.26%
1 month-8.96%
3 months-18.22%
6 months-39.88%
Current year-45.48%
1 week 3.8
Extreme 3.8
4.03
1 month 3.8
Extreme 3.8
4.52
Current year 3.8
Extreme 3.8
7.34
1 year 3.8
Extreme 3.8
9.16
3 years 3.8
Extreme 3.8
28.67
5 years 3.8
Extreme 3.8
62.08
10 years 3.8
Extreme 3.8
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap.
15/7/26 Free

CHIEF PROD & SUPPLY CHAIN OFF

60,000 0.1580%
15/7/26 Free

Chief Technology Officer

60,000 0.1580%
15/7/26 Free

Chief Operating Officer

60,000 0.1580%
Change 5-day change 1-year change 3-year change Capi.($)
-3.74%-0.26%-54.69%-84.31% 269M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.49%-3.44%+25.56%+133.18% 23.41B
Weighted average by Cap. +0.23%-2.96%+28.58%+119.74%

Financials

2026 *2027 *
Net sales 17.14M 14.9M 13.87M 12.73M 24.04M 1.64B 24.41M 163M 64.15M 814M 64.36M 62.95M 2.73B 6.75M 5.87M 5.46M 5.02M 9.47M 645M 9.62M 64.42M 25.28M 321M 25.36M 24.81M 1.08B
Net income -186M -162M -151M -138M -261M -17.79B -266M -1.78B -698M -8.86B -700M -685M -29.7B -171M -149M -139M -127M -241M -16.37B -244M -1.64B -642M -8.15B -644M -630M -27.33B
Net Debt -451M -392M -365M -335M -633M -43.07B -643M -4.3B -1.69B -21.44B -1.69B -1.66B -71.91B -406M -353M -328M -301M -569M -38.74B -578M -3.87B -1.52B -19.29B -1.52B -1.49B -64.68B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
31/07/26 USD 3.860 -3.74% 336,076
30/07/26 USD 4.010 +3.89% 418,975
29/07/26 USD 3.860 -2.03% 352,219
28/07/26 USD 3.940 -0.25% 320,853
27/07/26 USD 3.950 +2.07% 303,823
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.860USD
Average target price
9.857USD
Spread / Average Target
+155.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock